Skip to Content

Insulin Resistance, RAAS, HDL, and VLDL: How Molecular Pathways Drive Cardiometabolic Risk

Non-communicable diseases like type 2 diabetes and cardiovascular disease do not appear overnight. They develop over years through subtle, interconnected changes in metabolism, hormones, and blood vessels.

Four key players are at the heart of this process:

  • Insulin resistance

  • RAAS (Renin–Angiotensin–Aldosterone System)

  • HDL (“good”) cholesterol

  • VLDL (Very-Low-Density Lipoprotein)

Together, they form a biological network that links obesity, high blood pressure, dyslipidemia, and atherosclerosis. Understanding how these elements interact helps researchers, clinicians, and students grasp the deeper mechanisms behind metabolic syndrome and cardiovascular risk.

1. Insulin Resistance: The Metabolic Starting Point

Insulin resistance is a condition in which cells in the liver, muscle, and adipose tissue do not respond properly to insulin. For a given amount of insulin, less glucose is taken up and used.

How Insulin Normally Works

Under healthy conditions:

  • After a meal, blood glucose rises.

  • The pancreas releases insulin.

  • Insulin binds to its receptor on target cells.

  • Intracellular pathways (such as PI3K–Akt) are activated.

  • Glucose transporters (GLUT4 in muscle and adipose tissue) move to the cell membrane, allowing glucose entry.

  • The liver reduces glucose production and increases glycogen synthesis.

This keeps blood sugar in a narrow, safe range.

What Happens in Insulin Resistance

In insulin resistance:

  • The insulin receptor and downstream signaling molecules are less responsive.

  • Muscle and adipose tissue take up less glucose.

  • The liver continues to produce glucose even when it is not needed.

  • The pancreas compensates by secreting more insulin (hyperinsulinemia).

Over time, this leads to:

  • Elevated fasting blood glucose

  • Prediabetes and type 2 diabetes

  • Changes in lipid metabolism (increased VLDL, decreased HDL)

  • Effects on blood vessels and blood pressure

Insulin resistance is strongly influenced by visceral obesity, chronic low-grade inflammation, excess free fatty acids, oxidative stress, and sedentary lifestyle.

2. RAAS: The Hormonal Regulator of Blood Pressure and Volume

The Renin–Angiotensin–Aldosterone System (RAAS) is a hormone system that regulates blood pressure, fluid balance, and vascular tone.

The RAAS Cascade

  • The kidneys produce renin in response to low blood pressure, low sodium, or sympathetic nervous system activation.

  • Renin converts angiotensinogen into angiotensin I.

  • Angiotensin-converting enzyme (ACE), mainly in the lungs, converts angiotensin I into angiotensin II.

  • Angiotensin II:

    • Constricts blood vessels (vasoconstriction)

    • Stimulates aldosterone secretion from the adrenal cortex

  • Aldosterone:

    • Promotes sodium and water retention in the kidneys

    • Increases blood volume and blood pressure

RAAS and Metabolic Disease

In obesity and insulin resistance, RAAS is often overactivated:

  • Adipose tissue itself can produce angiotensinogen, contributing to RAAS activation.

  • Angiotensin II promotes:

    • Vascular inflammation

    • Endothelial dysfunction

    • Myocardial and vascular hypertrophy

This leads to:

  • High blood pressure (hypertension)

  • Accelerated atherosclerosis

  • Greater risk of heart attack, stroke, and kidney disease

RAAS blockers (ACE inhibitors, ARBs, mineralocorticoid receptor antagonists) are effective therapies because they target this fundamental pathway.

3. HDL: The “Good” Cholesterol and Vascular Protector

High-Density Lipoprotein (HDL) is often referred to as the “good” cholesterol, but its role is more complex than a simple number on a lab report.

Functions of HDL

HDL particles:

  • Participate in reverse cholesterol transport:

    • They collect excess cholesterol from peripheral tissues and from macrophages in arterial walls.

    • They deliver it back to the liver for processing and excretion.

  • Provide anti-inflammatory, antioxidant, and anti-thrombotic effects on the vascular endothelium.

  • Help maintain endothelial function and protect against plaque formation.

Higher HDL levels, and more importantly high-functioning HDL, are associated with a lower risk of cardiovascular disease.

Low HDL in Metabolic Syndrome

In metabolic syndrome and insulin resistance:

  • HDL levels tend to be low.

  • HDL particles can become dysfunctional due to oxidation and inflammation.

  • They are cleared more rapidly from the circulation after becoming enriched with triglycerides.

Low HDL is a key component of atherogenic dyslipidemia, a lipid profile strongly associated with increased cardiovascular risk.

4. VLDL: The Triglyceride Carrier with Atherogenic Consequences

Very-Low-Density Lipoprotein (VLDL) is produced by the liver and is rich in triglycerides. Its main role is to transport triglycerides to tissues for energy storage or use.

How VLDL Is Produced

  • When caloric intake (especially carbohydrates and fats) exceeds immediate energy needs, the liver synthesizes triglycerides.

  • These triglycerides are packaged into VLDL particles and released into the bloodstream.

  • As VLDL circulates, lipoprotein lipase (LPL) hydrolyzes triglycerides, allowing fatty acids to be taken up by muscle and adipose tissue.

  • VLDL is gradually remodeled into intermediate-density lipoprotein (IDL) and then LDL.

VLDL in Insulin Resistance

In insulin-resistant states:

  • Adipose tissue releases more free fatty acids due to impaired insulin suppression of lipolysis.

  • The liver takes up these fatty acids and increases VLDL production.

  • Insulin resistance also reduces LPL activity, slowing VLDL clearance.

The result is hypertriglyceridemia (high blood triglycerides), with more VLDL particles in circulation.

This excess VLDL:

  • Promotes formation of small, dense LDL, which is more atherogenic.

  • Interacts with HDL via cholesteryl ester transfer protein (CETP), enriching HDL with triglycerides and leading to rapid HDL catabolism (contributing to low HDL).

5. How These Pathways Interact: One Network, Multiple Risk Factors

Although insulin resistance, RAAS, HDL, and VLDL are often discussed separately, they are deeply interconnected in cardiometabolic disease.

Insulin Resistance and Lipids (HDL & VLDL)

  • Insulin resistance in adipose tissue → increased release of free fatty acids.

  • Liver takes up more fatty acids → increased VLDL production → high triglycerides.

  • Triglyceride-rich VLDL exchanges lipids with HDL → HDL becomes triglyceride-rich and is cleared faster → low HDL.

  • Thus, insulin resistance directly drives an atherogenic lipid profile: high VLDL / triglycerides + low HDL.

Insulin Resistance and RAAS

  • Hyperinsulinemia and obesity can activate the sympathetic nervous system and RAAS.

  • Adipose tissue secretes angiotensinogen, feeding into the RAAS cascade.

  • RAAS activation → vasoconstriction, sodium retention, vascular remodeling → high blood pressure.

  • Angiotensin II and aldosterone promote inflammation, oxidative stress, and fibrosis, worsening insulin resistance and vascular damage.

Lipids, Inflammation, and Vessels

  • Excess VLDL and small dense LDL infiltrate the arterial wall, where they can be oxidized and taken up by macrophages, forming foam cells and atherosclerotic plaque.

  • Low HDL reduces reverse cholesterol transport and the anti-inflammatory protection of arteries.

  • RAAS activation and hyperglycemia amplify oxidative stress, endothelial dysfunction, and plaque instability.

In summary:

Insulin resistance, RAAS activation, high VLDL, and low HDL form a self-reinforcing network that drives metabolic syndrome, type 2 diabetes, and cardiovascular disease.

6. Clinical and Research Implications

Understanding these interactions has important consequences for prevention and treatment.

Therapeutic Targets

  • Insulin resistance: Lifestyle interventions (diet, physical activity, weight loss) and insulin-sensitizing medications.

  • RAAS: ACE inhibitors, ARBs, and mineralocorticoid receptor antagonists to lower blood pressure and protect heart and kidneys.

  • Dyslipidemia (HDL/VLDL):

    • Statins and other lipid-lowering agents to reduce LDL and VLDL remnants.

    • Fibrates and omega-3 fatty acids in selected patients to lower triglycerides.

    • Emerging therapies targeting triglyceride metabolism and lipoprotein pathways.

Research Directions

For platforms like GlobalNCD, key research areas include:

  • Molecular mechanisms linking insulin resistance to RAAS activation and vascular injury.

  • Functional assessment of HDL (not just HDL cholesterol level) as a biomarker.

  • Systems biology approaches to integrate glucose, lipid, and blood pressure regulation.

  • Identification of biomarkers for early detection and risk stratification in cardiometabolic disease.

7. From Mechanisms to Prevention

While these pathways are complex, the key message for public health is clear:

  • Reducing insulin resistance through healthy diet, physical activity, and weight management improves glucose control, lipid profile, and blood pressure.

  • Targeting RAAS pharmacologically and through lifestyle change helps protect the heart, brain, and kidneys.

  • Managing triglycerides and HDL improves vascular health and reduces cardiovascular risk.

By connecting molecular mechanisms with clinical action, we can move from understanding disease to preventing it.